Business Wire

ALIPAY+

16.12.2022 05:08:36 CET | Business Wire | Press release

Share
Over 1 Million Global Merchants Join Alipay+ to Provide Special Holiday Offers to Users of Five Asian e-Wallets

Alipay+, the provider of global cross-border digital payments and marketing solutions, today rolled out its first year-end promotion campaign with merchants across Asia and Europe, in collaboration with five Asian e-wallet partners - AlipayHK (Hong Kong SAR, China), GCash (Philippines), Kakao Pay (South Korea), TrueMoney (Thailand) and Touch ‘n Go eWallet (Malaysia).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221215006131/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Great in-destination merchant offers are available where Alipay+ operates, including Japan, South Korea, Singapore and various countries in Europe. (Graphic: Business Wire)

The promotion campaign sees the participation of over one million merchants in retail, F&B, tourist attractions and hospitality across major travel destinations where Alipay+ is accepted, including Japan, South Korea, Singapore, and various countries in Europe. During the campaign period, users of participating e-wallets can enjoy a wide range of deals offered by Alipay+ together with merchant partners in each destination.

Leveraging the Alipay+ marketing solutions, merchants are able to create and customize promotions in the forms of either digital coupons or instant discounts. Merchants can also distribute digital coupons in multiple e-wallet apps at the same time to achieve better marketing efficiency and scalability.

Japan

Between 15 December 2022 and 15 February 2023, users of AlipayHK, GCash, Kakao Pay, TrueMoney and Touch ’n Go eWallet will receive three coupons in their respective apps upon arrival in Japan. Each of the three coupons offers a ¥50 discount with a minimum of ¥51 spent, and can be redeemed at all local merchants accepting Alipay+ payments across Japan.

In addition, Alipay+ has also introduced other merchant-specific coupons. Such offers include, but are not limited to:

  • ¥1,000 OFF with a minimum of ¥5,000 spent at merchants such as Daimaru Department Store, Keio Department Store, Kintetsu Department Store, merchants at Fukuoka Airport, BicCamera stores, and many others.
  • ¥500 OFF with a minimum of ¥3,000 spent at merchants such as Tsuruha Drug Store, Sapporo Drug Store, and many others.

E-wallet users are able to access and browse all merchant-specific coupons in their respective apps.

Through the integration of Alipay+ solutions, over one million brick-and-mortar merchants in Japan including airports, shopping malls, convenience stores, cafes, and restaurants are now able to accept various mobile payment methods.

South Korea

From now till the end of December, users of AlipayHK, GCash, TrueMoney and Touch ‘n Go eWallet can redeem digital coupons by simply using the respective e-wallets to scan the Alipay+ in-store promotion QR code displayed at the store cashiers, and enjoy instant discounts of up to 10%, when they pay with their e-wallets via Alipay+ at local merchants.

Participating merchants include F&B brands like Paris Baguette, Haidilao, retailers such as Daiso, Galleria Department Store, as well as Lotte Duty Free, Shinsegae Duty Free, etc. Over 120,000 merchants in South Korea are now accept the payments made by these four e-wallets via Alipay+.

Singapore

From now till 31 January 2023, users of AlipayHK, GCash, Kakao Pay, TrueMoney and Touch ’n Go eWallet will be given three coupons upon arrival in Singapore and enjoy savings when shopping in Singapore.

  • Coupon 1: SGD 1 off with a minimum of SGD 1.01 spent
  • Coupon 2: SGD 3 off with a minimum of SGD 3.01 spent
  • Coupon 3: SGD 8 off with a minimum of SGD 100 spent

Furthermore, Alipay+ has extended more promotions with various merchants at Changi Airport and Paragon Shopping Centre. Between 15 December 2022 and 31 January 2023, e-wallet users can enjoy three more deals:

  • Coupon 1: SGD 5 off with a minimum of SGD 20 spent;
  • Coupon 2: SGD 10 off with a minimum of SGD 100 spent;
  • Coupon 3: SGD 18 off with a minimum of SGD 200 spent.

When taking a ComfortDelgro Taxi in Singapore, users can also claim SGD 2 off with a minimum spending of SGD 2.01.

Each e-wallet user can redeem up to three coupons during the campaign period.

Europe

In France, UK, Italy and Germany, Alipay+ has rolled out various promotions and deals with local merchants, including retail stores Printemps in France and city-wide vending machines in Milan, Rome and Venice to reward shoppers this holiday season.

Between now and 31 January 2023, users of Kakao Pay, GCash, TrueMoney and Touch ‘n Go eWallet can enjoy up to 10 EUR in instant discounts when paying with the respective e-wallets at the aforementioned merchants. In addition, Printemps in France is also offering e-wallet users a special 5% store-wide discount and a free bubble tea voucher at the Printemps Haussmann store. E-wallet users can visit the store information desks to check for specific details.

As of November 2022, Alipay+’s merchant coverage has reached 2.5 million. Its merchant network includes regional and global digital entertainment providers, lifestyle services, e-commerce platforms and a wide range of brick-and-mortar businesses that cover major airports, shopping centers, duty free shops, convenience stores, cafes, restaurants and tourism facilities.

The global merchant coverage of Alipay+ by sector includes over 1,000 online platforms, more than 10 major airports, over 90,000 convenience stores, over 360,000 restaurants, nearly 200,000 taxis and major hotel brands, department stores, duty-free shops and tourist facilities in Asia and Europe.

*Terms and conditions apply in coupon usage and redemption.

About Alipay+

Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods from different countries and regions by collaborating with global partners. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing offers by the merchants through Alipay+. Alipay+ is developed by Ant Group, the owner and operator of Alipay, one of the world’s leading digital open platforms.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221215006131/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye